FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324376477> ?p ?o ?g. }

• W2324376477 endingPage "398" @default.
• W2324376477 startingPage "393" @default.
• W2324376477 abstract "Objectives: Preoperative chemotherapy and radiation for localized esophageal cancer produces cure rates near 30% when combined with surgical resection. Vandetanib, a small molecule receptor tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, RET, and EGFR, demonstrated synergy with radiation and chemotherapy in preclinical models. We conducted a phase I study to assess the safety and tolerability of vandetanib when combined with preoperative chemoradiation in patients with localized esophageal carcinoma who were surgical candidates. Methods: Patients with stage II-III esophageal and gastroesophageal junction carcinoma without prior therapy were enrolled in a 3+3 phase I design. Patients received once-daily vandetanib (planned dosing levels of 100, 200, and 300 mg) with concomitant daily radiotherapy (1.8 Gy/d, 45 Gy total) and chemotherapy, consisting of infusional 5-FU (225 mg/m 2 /d over 96 h, weekly), paclitaxel (50 mg/m 2 , days 1, 8, 15, 22, 29) and carboplatin (AUC of 5, days 1, 29). Results: A total 9 patients were enrolled with 8 having either distal esophageal or gastroesophageal junction carcinomas. All patients completed the planned preoperative chemoradiation and underwent esophagectomy. Nausea (44%) and anorexia (44%) were the most common acute toxicities of any grade. One grade 4 nonhematologic toxicity was observed (gastrobronchial fistula). One additional patient suffered a late complication, a fatal aortoenteric hemorrhage, not definitively related to the investigational regimen. Five (56%) patients achieved a pathologic complete response. Three (33%) additional patients had only microscopic residual disease. Five (56%) patients remain alive and disease free with a median follow-up of 3.7 years and median overall survival of 3.2 years. The maximum tolerated dose was vandetanib 100 mg/d. Conclusions: Vandetanib at 100 mg daily is tolerable in combination with preoperative chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy with encouraging efficacy worthy of future study." @default.
• W2324376477 created "2016-06-24" @default.
• W2324376477 creator A5017605264 @default.
• W2324376477 creator A5021531753 @default.
• W2324376477 creator A5023000705 @default.
• W2324376477 creator A5046909879 @default.
• W2324376477 creator A5052704200 @default.
• W2324376477 creator A5065431287 @default.
• W2324376477 creator A5069585958 @default.
• W2324376477 creator A5076091049 @default.
• W2324376477 creator A5076736008 @default.
• W2324376477 creator A5078226344 @default.
• W2324376477 creator A5087332592 @default.
• W2324376477 creator A5089998052 @default.
• W2324376477 creator A5090126068 @default.
• W2324376477 date "2017-08-01" @default.
• W2324376477 modified "2023-09-29" @default.
• W2324376477 title "Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer" @default.
• W2324376477 cites W1973840209 @default.
• W2324376477 cites W1977468182 @default.
• W2324376477 cites W1995318267 @default.
• W2324376477 cites W1998482951 @default.
• W2324376477 cites W2003323566 @default.
• W2324376477 cites W2004394004 @default.
• W2324376477 cites W2027815217 @default.
• W2324376477 cites W2031200807 @default.
• W2324376477 cites W2051277839 @default.
• W2324376477 cites W2054305985 @default.
• W2324376477 cites W2062316437 @default.
• W2324376477 cites W2063573198 @default.
• W2324376477 cites W2067813478 @default.
• W2324376477 cites W2069547811 @default.
• W2324376477 cites W2071865962 @default.
• W2324376477 cites W2099462532 @default.
• W2324376477 cites W2107666024 @default.
• W2324376477 cites W2108088675 @default.
• W2324376477 cites W2111060860 @default.
• W2324376477 cites W2111674123 @default.
• W2324376477 cites W2112768035 @default.
• W2324376477 cites W2127996441 @default.
• W2324376477 cites W2135708639 @default.
• W2324376477 cites W2136935697 @default.
• W2324376477 cites W2138133809 @default.
• W2324376477 cites W2154444715 @default.
• W2324376477 cites W2160019071 @default.
• W2324376477 cites W2165948908 @default.
• W2324376477 cites W2166081217 @default.
• W2324376477 cites W2241941123 @default.
• W2324376477 cites W2333224485 @default.
• W2324376477 doi "https://doi.org/10.1097/coc.0000000000000171" @default.
• W2324376477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5026539" @default.
• W2324376477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26986978" @default.
• W2324376477 hasPublicationYear "2017" @default.
• W2324376477 type Work @default.
• W2324376477 sameAs 2324376477 @default.
• W2324376477 citedByCount "7" @default.
• W2324376477 countsByYear W23243764772020 @default.
• W2324376477 countsByYear W23243764772021 @default.
• W2324376477 countsByYear W23243764772022 @default.
• W2324376477 countsByYear W23243764772023 @default.
• W2324376477 crossrefType "journal-article" @default.
• W2324376477 hasAuthorship W2324376477A5017605264 @default.
• W2324376477 hasAuthorship W2324376477A5021531753 @default.
• W2324376477 hasAuthorship W2324376477A5023000705 @default.
• W2324376477 hasAuthorship W2324376477A5046909879 @default.
• W2324376477 hasAuthorship W2324376477A5052704200 @default.
• W2324376477 hasAuthorship W2324376477A5065431287 @default.
• W2324376477 hasAuthorship W2324376477A5069585958 @default.
• W2324376477 hasAuthorship W2324376477A5076091049 @default.
• W2324376477 hasAuthorship W2324376477A5076736008 @default.
• W2324376477 hasAuthorship W2324376477A5078226344 @default.
• W2324376477 hasAuthorship W2324376477A5087332592 @default.
• W2324376477 hasAuthorship W2324376477A5089998052 @default.
• W2324376477 hasAuthorship W2324376477A5090126068 @default.
• W2324376477 hasBestOaLocation W23243764772 @default.
• W2324376477 hasConcept C121608353 @default.
• W2324376477 hasConcept C126322002 @default.
• W2324376477 hasConcept C141071460 @default.
• W2324376477 hasConcept C170493617 @default.
• W2324376477 hasConcept C197934379 @default.
• W2324376477 hasConcept C2776694085 @default.
• W2324376477 hasConcept C2777297899 @default.
• W2324376477 hasConcept C2777546739 @default.
• W2324376477 hasConcept C2778239845 @default.
• W2324376477 hasConcept C2778375690 @default.
• W2324376477 hasConcept C2778496288 @default.
• W2324376477 hasConcept C2779384505 @default.
• W2324376477 hasConcept C2779742542 @default.
• W2324376477 hasConcept C2780333294 @default.
• W2324376477 hasConcept C2781413609 @default.
• W2324376477 hasConcept C2781451048 @default.
• W2324376477 hasConcept C42362537 @default.
• W2324376477 hasConcept C509974204 @default.
• W2324376477 hasConcept C71924100 @default.
• W2324376477 hasConcept C90924648 @default.
• W2324376477 hasConceptScore W2324376477C121608353 @default.
• W2324376477 hasConceptScore W2324376477C126322002 @default.
• W2324376477 hasConceptScore W2324376477C141071460 @default.

• next